Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Feed Additive Developer Signs MOU with Philippine Distributor
News Update

Share on Stocktwits


This is the first step toward a binding, definitive agreement between the two companies.

Avivagen Inc. (VIV:TSX.V; CHEXF:OTCMKTS) announced in a news release it signed a memorandum of understanding (MOU) with INPHILCO for it to distribute Avivagen's OxC-beta™ Livestock in the Philippines.

The MOU represents the start of negotiating a binding definitive agreement between the two companies, which they both expect to reach and sign in the next two months.

Under the MOU, INPHILCO will sell the non-antibiotic feed additive for swine and poultry to large integrated feed producers in two ways. One is as part of INPHILCO'S premix offerings. The other is as a standalone product and to commercial farms throughout the country.

"INPHILCO's deep rooted relationships with both large integrated feed producers and commercial farms, along with its well-earned reputation for high quality feed premixes, provide an opportunity for OxC-beta Livestock use for both swine and poultry to grow in the Philippines over the coming years," Avivagen CEO Kym Anthony said in the release.

In other news, Avivagen is finalizing the rights to sell OxC-beta Livestock directly to Quezon City-based Universal Robina Corp., a large producer of integrated livestock branded consumer foods and beverages. Universal Robina's Agro-Industrial and Commodity Food Groups, a major pork and poultry producer in the Philippines, is currently testing OxC-beta Livestock in its integrated feed for use in its swine operations.

"When signed, these important new agreements with INPHILCO and Universal Robina will help OxC-beta Livestock reach an even greater segment of the Philippine feed market," Anthony added.

"Avivagen expects growth within the Asia-Pacific market to accelerate in 2020 and beyond as new applications of OxC-beta are being utilized by a growing number of local partners, and as it pursues additional regulatory approvals in new jurisdictions," the company stated. The company recently secured approval for OxC-beta Livestock for specific applications in Taiwan, Mexico, Malaysia and the United States.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Want to read more about Nutraceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe